These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36153246)

  • 1. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint.
    Powell K; Burns MC; Prasad V
    Eur Urol; 2023 Feb; 83(2):101-102. PubMed ID: 36153246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101-2.
    Montorsi F; Scuderi S; Briganti A; Gandaglia G
    Eur Urol; 2023 May; 83(5):e136. PubMed ID: 36774225
    [No Abstract]   [Full Text] [Related]  

  • 3. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
    Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
    Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
    Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
    Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
    Shore ND; Sutton J
    Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.
    Slater H
    Oncology (Williston Park); 2020 Jul; 34(7):252. PubMed ID: 32674208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
    Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.
    Lv J; Lin J
    Asian J Androl; 2021; 23(3):229-230. PubMed ID: 33243960
    [No Abstract]   [Full Text] [Related]  

  • 12. Relugolix: First Global Approval.
    Markham A
    Drugs; 2019 Apr; 79(6):675-679. PubMed ID: 30937733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Chow AK; Vourganti S; Konety BR
    Eur Urol; 2021 Sep; 80(3):386. PubMed ID: 34092438
    [No Abstract]   [Full Text] [Related]  

  • 15. First Oral Hormone for Treating Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2021 Apr; 121(4):22-23. PubMed ID: 33755620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Mahal BA; D'Amico AV; Nguyen PL
    Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
    [No Abstract]   [Full Text] [Related]  

  • 17. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.
    Sachdev S; Zhang H; Hussain M
    Eur Urol; 2020 Aug; 78(2):193-194. PubMed ID: 32345524
    [No Abstract]   [Full Text] [Related]  

  • 19. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.